These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34511184)

  • 1. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor.
    Kokado Y; Kawai K; Nanjo T; Kinoshita S; Kondo K
    Clin Ther; 2021 Aug; 43(8):1408-1418.e5. PubMed ID: 34511184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults.
    Paulson SK; Martinez J; Sawant R; Burke SK; Chavan A
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):475-485. PubMed ID: 35172045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
    Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
    Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease.
    Navarro-Gonzales P; Ganz T; Pergola PE; Zuk A; Dykstra K
    Clin Pharmacol Ther; 2024 Oct; 116(4):1052-1061. PubMed ID: 38924087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
    Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
    N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
    Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
    Imai E; Imai A
    Intern Med; 2024 Jul; 63(13):1855-1861. PubMed ID: 37926547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
    Nangaku M; Farag YMK; deGoma E; Luo W; Vargo D; Khawaja Z
    Nephrol Dial Transplant; 2020 Jul; ():. PubMed ID: 32719868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
    Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
    Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
    Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
    Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.
    Mimura I; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1111-1120. PubMed ID: 38896547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure.
    Yazaki M; Nabeta T; Takigami Y; Eda Y; Fujita T; Iida Y; Ikeda Y; Ishii S; Ako J
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256345
    [No Abstract]   [Full Text] [Related]  

  • 19. Vadadustat: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(13):1365-1371. PubMed ID: 32852744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents.
    Kowalski H; Hoivik D; Rabinowitz M
    Toxicol Pathol; 2023 Jan; 51(1-2):56-60. PubMed ID: 37158494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.